Alan H B Wu: Cardiac Markers (kartoniertes Buch)

InhaltsangabePart I. Cardiac Markers in Clinical Practice Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols Andra L. Blomkalns and W. Brian Gibler Management of Acute Coronary Syndromes Constantine N. Aroney and James A. de Lemos Evolution of Cardiac Markers in Clinical Trials Alexander S. Ro and Christopher R. deFilippi Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise Robert H. Christenson and Hassan M. E. Azzazy The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents Eugene H. Herman, Steven E. Lipshultz, and Victor J. Ferrans The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery Jesse E. Adams, III Part II. Clinical Use for Cardiac Troponins Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications Ralf Labugger, D. Kent Arrell, and Jennifer E. Van Eyk Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients Fred S. Apple CardiacSpecific Troponins Beyond Ischemic Heart Disease David Morrow Part III. Analytical Issues for Cardiac Markers Antibody Selection Strategies in Cardiac Troponin Assays Alexei Katrukha Interferences in Immunoassays for Cardiac Troponin KiangTeck J. Yeo and Daniel M. Hoefner Cardiac Marker Measurement by Point-of-Care Testing Paul O. Collinson Standardization of Cardiac Markers Mauro Panteghini Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers Alan H. B. Wu Part IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes Robert L. Jesse IschemiaModified Albumin, Free Fatty Acids, Whole Blood Choline, BType Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin Alan H. B. Wu, Peter Crosby, Gary Fagan, Oliver Danne, Ulrich Frei, Martin Möckel, and Joseph Keffer CReactive Protein for Primary Risk Assessment Gavin J. Blake and Paul M. Ridker Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes Luigi M. Biasucci, Antonio Abbate, and Giovanna Liuzzo Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement Thomas B. Ledue and Nader Rifai Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification Jan F. C. Glatz, Roy F. M. van der Putten, and Wim T. Hermens Oxidized LowDensity Lipoprotein and MalondialdehydeModified LowDensity Lipoprotein in Patients with Coronary Artery Disease Paul Holvoet Part V. Cardiac Markers of Congestive Heart Failure Pathophysiology of Heart Failure Johannes Mair BType Natriuretic Peptide: Biochemistry and Measurement Jeffrey R. Dahlen BType Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure Ramin Tabbibizar and Alan Maisel Monitoring Efficacy of Treatment with Brain Natriuretic Peptide Emil D. Missov and Leslie W. Miller NTerminal ProBType Natriuretic Peptide Torbjørn Omland and Christian Hall Part VI. Role of Infectious Diseases and Genetics in Heart Disease Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae Martin Möckel Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics Alan H. B.

In this greatly enlarged and thoroughly updated edition of his much praised Cardiac Markers, Alan Wu and his contributors focus on the use of markers in the practice of cardiology and-for the first time-on the use of natriuretic peptides for congestive heart failure. Here, leading international authorities in clinical chemistry and laboratory medicine, cardiology, emergency medicine, and the in vitro diagnostics industry describe the state-of-the-art uses of cardiac markers when treating coronary artery disease, and discuss in detail how they may be optimally used in a clinical setting. The many new and updated chapters introduce new ischemic markers such as CRP, fatty acid binding protein, ischemia modified albumin, oxidized LDL, whole blood choline, and genetic polymorphisms that portend high risk for cardiovascular disease. The authors address analytical issues, assay development, cutoff concentrations, antibody selection schemes, point-of-care testing, in situ degradation of cardiac troponin, and updated clinical trials. They also discuss the emerging infectious disease etiology of heart disease, as well as the role of troponin in such non-ischemic diseases as renal failure, cardiac surgery, sepsis, myocarditis, and chemotherapeutic drug monitoring. Comprehensive and cutting-edge, Cardiac Markers, Second Edition not only offers physicians a complete guide to the use of cardiac markers in clinical practice, but also provides clinical laboratorians a close-up view of the new markers now becoming standard.